2019 ASCEPT-PAGANZ scientific program
Tuesday 26 November – 17:00 Meeting open and keynote presentation
Friday 29 November – 13:00 Meeting close
Pre-meeting workshops
Monday 25 November 2019
08:30 – 17:00 Beginner Population Approach workshop (pharmacometrics)
08:30 – 17:00 Intermediate Population Approach workshop (pharmacometrics)
Population Approach workshop (pharmacometrics)
The PAWS courses will consist of lectures and hands-on exercises using modelling programmes such as NONMEM and R. Please note that there will not be a computer room at the venue and all software will be accessed via a virtual desktop (based at the University of Otago in Dunedin). Please bring a suitable computing device to the workshop; one that has an internet browser, a USB port, and, preferably a mouse and a keyboard.
During the hands-on exercises, tutors will be available for consultation and assistance. The Beginners workshop and the Intermediate Course will be conducted as parallel sessions.
The beginners PAWS will introduce the theory and practice of population modelling with a hands on session with NONMEM and will be delivered by the Otago Pharmacometrics Research group. No prior experience is necessary.
The intermediate PAWS will introduce and run through model simulation and estimation using the open-source R-based non-linear mixed effect modelling platform nlmixr. Dr Rik Schoemaker, on behalf of the nlmixr development team, will facilitate this session. Attendance at the Intermediate workshop requires experience with the conduct of at least one population approach analysis.
The PAWS workshops include morning tea, lunch and afternoon tea.
Thank you to our supporters.
Tuesday 26 November 2019
08:30 – 12:30 Clinical Pharmacology workshop
08:30 Welcome and introduction Assoc Prof Matt Doogue, University of Otago, Christchurch
Part 1 – The Principles of Dosing
08:40 – 09:10 Pharmacokinetic principles and dosing Prof Evan Begg, University of Otago, Christchurch
09:10 – 09:40 Choosing the dose Prof Steve Duffull, School of Pharmacy, University of Otago
09:40 – 10:10 Dosing patients today Dr Phil Drennan, Royal Prince Alfred Hospital, University of Sydney
10:10 – 10:30 Panel Discussion
10:30 – 11:00 Comfort break
Part 2 – Going Beyond the Label
11:00 – 12:30 Group discussion to determine the “optimum” process to dose a selected medicine
We will split into groups and each group will be tasked with determining the “optimum” process to dose a selected medicine. You will be asked to determine initial doses and subsequent doses using whatever methods you deem appropriate AND to compare and contrast this with the current product information. Nominate a medicine by email to mdoogue@gmail.com.
12:30 – 13:00 Clinical Pharmacology SIG AGM
09:00 – 12:30 Innovation and impact workshop (Accelerating Australia)
Including an introduction to SPARK
Prof Michael Wallach, Director, SPARK Oceania
10:30 – 12:30 Pharmacogenomics workshop
10:30 – 10:35 Welcome & introduction Prof Andrew Somogyi, Chair ASCEPT Pharmacogenomics SIG
10:35 – 11:15 Application of new tools to understand the genetics of adverse drug reactions Prof Martin Kennedy, Carney Centre for Pharmacogenomics, University of Otago, Christchurch, New Zealand
11:15 – 11:40 Precision medicine for type 2 diabetes Assoc Prof Rinki Murphy, University of Auckland, Auckland, New Zealand
11:40 – 12:05 ECR/student talks
12:05 – 12:30 Pharmacogenomics SIG AGM
13:30 – 16:30 Education Forum
- Showcase of teaching initiatives
- Round table discussion of issues in pharmacology education
- Education Forum AGM
13:30 – 16:30 Neuropharmacology/Drug Discovery workshop
13:30 – 14:45 Student and ECR talks
14:45 – 15:00 Comfort break
15:00 – 16:15 Student and ECR talks
16:15 – 16:30
Drug Discovery SIG Meeting
Neuropharmacology SIG meeting
Joint Scientific Meeting
Tuesday 26 November, 17:00 Meeting open and keynote presentation
Friday 29 November, 13:00 Meeting close
Keynote speakers
Prof Daria Mochly-Rosen
Stanford University, USA
Daria Mochly-Rosen is a Professor of Chemical and Systems Biology and the George D. Smith Professor for Translational Medicine at Stanford University School of Medicine. She leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists and has used her basic research discoveries to develop a number of drug leads for human diseases with a particular interest in mitochondrial biology and pathology. Dr Mochly-Rosen served on many university leadership committees, was chair of her department (2001-2004) and the Senior Associate Dean for Research, Stanford University School of Medicine (between 2006 and 2013). She has published over 240 papers and over 30 patents and patent applications and has founded three companies: KAI Pharmaceuticals (2003-2011), ALDEA (now Aviv Therapeutics; 2013-) and Mitoconix (2016-).
Prof Steven Charlton,
School of Life Sciences, University of Nottingham, UK
Steven is Professor of Molecular Pharmacology and Drug Discovery at the University of Nottingham, where he is interested in all aspects of the quantitative assessment of ligand-receptor interactions. In particular he has expertise in the measurement and interpretation of the kinetics of ligand binding and signalling. Steven is also co-founder and Chief Scientific Officer at Excellerate Bioscience Ltd, a CRO providing specialist molecular pharmacology solutions to the drug discovery sector. Prior to these roles he spent 16 years in the pharmaceutical industry, both at SmithKline Beecham and Novartis. At Novartis he was Director of Molecular Pharmacology in Respiratory Diseases, leading an assay development and compound profiling team of 30 scientists providing expert opinion and support for GPCR, ion channel and enzyme projects. He has broad drug discovery experience, ranging from target validation through to leading full lead optimisation programmes to successful clinical proof of concept. Steven was awarded Novartis Leading Scientist in 2007.
Dr John Thompson
National Poisons Information Service, UK
Dr John Thompson is Director of the National Poisons Information Service (Cardiff), one of four units responsible for delivering advice on the management of poisoned patients within the United Kingdom and which also provides services internationally. He is the national lead for the United Kingdom Poisons Information Database (UKPID) and was previously Head of the Chemical Incident Management Support Unit, advising on the management of chemical incidents and is a consultant to the World Health Organisation Collaborating Centre for the Public Health Management of Chemical Exposures. Dr Thompson is Senior Lecturer in Clinical Pharmacology at Cardiff University. Clinically, in addition to providing general internal medicine services, Dr Thompson is the lead consultant for a specialised eight-bedded poisons treatment unit and delivers specialty clinics in toxicology, hypertension and adverse drug reactions.
Prof Andrew McLachlan
The University of Sydney School of Pharmacy, AUS
Professor Andrew McLachlan is a pharmacist, academic and researcher with experience in clinical pharmacology and the quality use of medicines. He is Head of School and Dean at The University of Sydney School of Pharmacy. Andrew is the Program Director of a NHMRC Centre for Research Excellence in Medicines and Ageing. He has served as the chair of a human research ethics committee and serves on Australian government committees related to medicines policy, evaluation, regulation and antidoping. He became a Member of the Order of Australia for his significant service to pharmacy as a researcher, educator and administrator, and to professional medical and scientific organisations.